Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced p...

Saved in:

書目詳細資料
Main Authors:	Tony S. Mok, Yi Long Wu, Sumitra Thongprasert, Chih Hsin Yang, Da Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour, Masahiro Fukuoka
格式:	雜誌
出版:	2018
主題:	Medicine
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=69949162760&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/49303
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	Chiang Mai University

相似書籍

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Wu Y., et al.
出版: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Masahiro Fukuoka, et al.
出版: (2018)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Sumitra Thongprasert, et al.
出版: (2018)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Thongprasert S., et al.
出版: (2014)

Lung cancer working group report
由: Nagahiro Saijo, et al.
出版: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Fukuoka M., et al.
出版: (2017)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Sumitra Thongprasert, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
由: Wong, A.S., et al.
出版: (2014)

A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer
由: Sumitra Thongprasert, et al.
出版: (2018)

Lung cancer working group report
由: Saijo N., et al.
出版: (2017)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Wu Y.-L., et al.
出版: (2014)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
由: Auliya Hafizah, Raysa

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma
由: Chalyut Charoentum, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
由: Wong, A.S., et al.
出版: (2014)

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry
由: Wang, L.-Z., et al.
出版: (2014)

Comparison Between Gemcitabine-Carboplatin and Combination of Gemcitabine-Carboplatin and Celecoxib in Urothelial Carcinoma Cell Apoptosis
由: Widya Sakti Pratama, et al.
出版: (2019)

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
由: Chaiyut Charoentum, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Lee C., et al.
出版: (2017)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
由: Afrita Amalia Laitupa, -, et al.
出版: (2019)

SYNTHESIS OF VARIOUS GEFITINIB INTERMEDIATE DERIVATIVE AS ANTI-CANCER DRUGS
由: Lutfi Sa'adah, Pipih

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
由: Sudo, M., et al.
出版: (2014)

Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial
由: Imjai Chitapanarux, et al.
出版: (2020)

Short-hairpin RNA library: Identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
由: Sudo M., et al.
出版: (2020)

The Differences of Apoptosis Effects Between Combination of Meloxicam with Gemcitabine-Carboplatin Chemotherapy Compared to Gemcitabine-Carboplatin Chemotherapy Alone in Urothelial Carcinoma Culture Cells
由: Ananta Cahyo Nugroho, et al.
出版: (2019)

Dietary counseling outcomes in locally advanced unresectable or metastatic cancer patients undergoing chemotherapy
由: Napawan Sukaraphat, et al.
出版: (2018)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
由: James Chih Hsin Yang, et al.
出版: (2018)

PERBEDAAN EFEK APOPTOSIS PEMBERIAN KOMBINASI MELOKSIKAM DAN KEMOTERAPI GEMCITABINE CARBOPLATIN DIBANDINGKAN KEMOTERAPI GEMCITABINE CARBOPLATIN PADA SEL KULTUR KARSINOMA UROTHELIAL
由: Ananta Cahyo Nugroho, NIM01131896305
出版: (2018)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
由: Mark Boye, et al.
出版: (2018)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
由: Kietpeerakool C., et al.
出版: (2014)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids
由: Barnham, K.J., et al.
出版: (2014)